IL166522A0 - Combination of zd6474 an inhibitor of the vascularendothelial growth factor receptor with radiother apy in the treatment of cancer - Google Patents

Combination of zd6474 an inhibitor of the vascularendothelial growth factor receptor with radiother apy in the treatment of cancer

Info

Publication number
IL166522A0
IL166522A0 IL16652205A IL16652205A IL166522A0 IL 166522 A0 IL166522 A0 IL 166522A0 IL 16652205 A IL16652205 A IL 16652205A IL 16652205 A IL16652205 A IL 16652205A IL 166522 A0 IL166522 A0 IL 166522A0
Authority
IL
Israel
Prior art keywords
radiother
apy
cancer
inhibitor
treatment
Prior art date
Application number
IL16652205A
Other languages
English (en)
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0218525A external-priority patent/GB0218525D0/en
Priority claimed from GB0307560A external-priority patent/GB0307560D0/en
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of IL166522A0 publication Critical patent/IL166522A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL16652205A 2002-08-09 2005-01-26 Combination of zd6474 an inhibitor of the vascularendothelial growth factor receptor with radiother apy in the treatment of cancer IL166522A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0218525A GB0218525D0 (en) 2002-08-09 2002-08-09 Combination therapy
GB0307560A GB0307560D0 (en) 2003-04-02 2003-04-02 Combination therapy
PCT/GB2003/003388 WO2004014383A1 (en) 2002-08-09 2003-08-05 Combination of zd6474, an inhibitor of the vascular endothelial growth factor receptor, with radiotherapy in the treatment of cancer

Publications (1)

Publication Number Publication Date
IL166522A0 true IL166522A0 (en) 2006-01-15

Family

ID=31716921

Family Applications (1)

Application Number Title Priority Date Filing Date
IL16652205A IL166522A0 (en) 2002-08-09 2005-01-26 Combination of zd6474 an inhibitor of the vascularendothelial growth factor receptor with radiother apy in the treatment of cancer

Country Status (13)

Country Link
US (1) US20050222183A1 (enExample)
EP (1) EP1534287A1 (enExample)
JP (1) JP2006502132A (enExample)
KR (1) KR20050056190A (enExample)
CN (1) CN1313094C (enExample)
AU (1) AU2003249000B2 (enExample)
BR (1) BR0313116A (enExample)
CA (1) CA2495487A1 (enExample)
IL (1) IL166522A0 (enExample)
MX (1) MXPA05001458A (enExample)
NO (1) NO20050450L (enExample)
NZ (1) NZ537753A (enExample)
WO (1) WO2004014383A1 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1244647E (pt) * 1999-11-05 2006-10-31 Astrazeneca Ab Derivados de quinazolina como inibidores de vegf
GB0008269D0 (en) * 2000-04-05 2000-05-24 Astrazeneca Ab Combination chemotherapy
IL151626A0 (en) 2000-04-07 2003-04-10 Astrazeneca Ab Quinazoline compounds
GB0126879D0 (en) * 2001-11-08 2002-01-02 Astrazeneca Ab Combination therapy
EP2292615A1 (en) * 2002-02-01 2011-03-09 AstraZeneca AB Quinazoline compounds
GB0218526D0 (en) * 2002-08-09 2002-09-18 Astrazeneca Ab Combination therapy
GB0223380D0 (en) * 2002-10-09 2002-11-13 Astrazeneca Ab Combination therapy
RU2350618C2 (ru) 2002-11-04 2009-03-27 Астразенека Аб ПРОИЗВОДНЫЕ ХИНАЗОЛИНА В КАЧЕСТВЕ ИНГИБИТОРОВ Src ТИРОЗИНКИНАЗЫ
DE602004032310D1 (de) * 2003-02-13 2011-06-01 Astrazeneca Ab Kombinationstherapie von zd6474 mit 5-fu oder/und cpt-11
GB0310401D0 (en) * 2003-05-07 2003-06-11 Astrazeneca Ab Therapeutic agent
JP2007526886A (ja) * 2003-07-10 2007-09-20 アストラゼネカ アクチボラグ 血管新生および／または血管透過性増大に関連する疾患の処置における、プラチナ系抗腫瘍剤および任意の電離放射線と組み合わせてのキナゾリン誘導体ｚｄ６４７４の使用
KR20070072543A (ko) * 2004-09-27 2007-07-04 아스트라제네카 아베 Ｚｄ6474 및 이마티닙을 포함하는 병합법
GB0424339D0 (en) * 2004-11-03 2004-12-08 Astrazeneca Ab Combination therapy
GB0519879D0 (en) 2005-09-30 2005-11-09 Astrazeneca Ab Chemical process
CA2631764A1 (en) * 2005-12-22 2007-06-28 Astrazeneca Ab Combination of zd6474 and pemetrexed
JP4945133B2 (ja) * 2006-01-19 2012-06-06 富士フイルムＲｉファーマ株式会社 ４−フェノキシキナゾリン誘導体放射性化合物
WO2008037996A1 (en) * 2006-09-29 2008-04-03 Astrazeneca Ab Combination of zd6474 and bevacizumab for cancer therapy
US20080190689A1 (en) * 2007-02-12 2008-08-14 Ballard Ebbin C Inserts for engine exhaust systems
WO2009118560A1 (en) * 2008-03-28 2009-10-01 Astrazeneca Ab Combination therapy 038
CN106317022A (zh) * 2015-06-25 2017-01-11 中美华世通生物医药科技（武汉）有限公司 化合物的制备方法和用途
CN106397401B (zh) * 2016-08-30 2018-11-13 山东罗欣药业集团股份有限公司 一种抗癌药物的晶体化合物及其制备方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1244647E (pt) * 1999-11-05 2006-10-31 Astrazeneca Ab Derivados de quinazolina como inibidores de vegf

Also Published As

Publication number Publication date
AU2003249000A1 (en) 2004-02-25
US20050222183A1 (en) 2005-10-06
CA2495487A1 (en) 2004-02-19
EP1534287A1 (en) 2005-06-01
WO2004014383A1 (en) 2004-02-19
JP2006502132A (ja) 2006-01-19
KR20050056190A (ko) 2005-06-14
CN1674905A (zh) 2005-09-28
NO20050450L (no) 2005-05-02
MXPA05001458A (es) 2005-06-06
CN1313094C (zh) 2007-05-02
NZ537753A (en) 2008-04-30
AU2003249000B2 (en) 2007-04-05
BR0313116A (pt) 2005-07-05

Similar Documents

Publication Publication Date Title
AU2003261100A1 (en) Devices delivering therapeutic agents and methods regarding the same
AU2003301662A8 (en) Quinazolinones and derivatives thereof as factor xa inhibitors
PL378879A1 (pl) Terapia skojarzona z czynnikami kostymulującymi
IL166780A0 (en) Use of ikappab-kinase inhibitors in pain therapy
AP2005003251A0 (en) New spirocondensed quinazolinones and their use asphosphodiesterase inhibitors.
AU2003235470A8 (en) Predictive markers in cancer therapy
AU2003212634A8 (en) Compounds useful in the treatment of cancer
TW551545U (en) Structure of power supply
GB0220214D0 (en) Compounds and their use
PL374581A1 (en) Diaminothiazoles and use thereof as cdk4 inhibitors
AU2003215257A8 (en) Modified defensins and their use
GB0207411D0 (en) Azole compounds and their therapeutic use
GB0219660D0 (en) Therapeutic use
EP1709305A4 (en) POWER SOURCE AND TRANSFORMER
AU2003251513A8 (en) Rsk inhibitors and therapeutic uses thereof
EP1569928A4 (en) THERAPEUTIC COMPOUNDS AND METHOD
AU2003296871A8 (en) Point feeder and use of point feeder
IL164951A0 (en) The treatment of pain with lfendropil
GB2392839A8 (en) Use of Mycobacterium w in the treatment of tubercolosis
GB0215773D0 (en) Compunds and their therapeutic use
GB0218031D0 (en) Compounds and their use
HK1076740A (en) Combination of zd6474, an inhibitor of the vascular endothelial growth factor receptor, with radiotherapy in the treatment of cancer
IL165935A0 (en) Use of vasopeptidase inhibitors in the treatment of nephropathy
GB0220215D0 (en) Compounds and their use
GB0207412D0 (en) Rhodanine compounds and their therapeutic use